RxDoctor Payments Data

Kyle Craig, MD

Family Medicine · Bartlesville, OKNPI 1528138633

Payments from drug & device makers

$757in general payments, 2019–2025

Across 17 payments — averaging $44.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galil Medical Inc.$507
  • Lilly USA, LLC$54
  • Pfizer$37
  • Novo Nordisk$32
  • Boston Scientific$27
  • Exact Sciences$27
  • plus $73 from 4 others

What the payments were for

  • Travel & lodging$50767%
  • Food & beverage$24933%

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Galil Medical Inc.4$507
Lilly USA, LLC3$54
Pfizer2$37
Novo Nordisk2$32
Boston Scientific1$27
Exact Sciences1$27
Seqirus USA Inc1$25
Axsome Therapeutics, Inc.1$19
GSK1$15
Bayer1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$757 in reported general payments places this provider in the 60th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$44,479
Medicare patients
226
Services billed
906

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide54$61,411
EliquisApixaban37$41,875
MounjaroTirzepatide26$26,583
XareltoRivaroxaban19$20,113
Tresiba Flextouch U-100Insulin Degludec15$14,987
JardianceEmpagliflozin15$11,237
FarxigaDapagliflozin Propanediol16$10,954
GemtesaVibegron11$8,824
SynjardyEmpagliflozin/Metformin Hcl12$7,883
TradjentaLinagliptin12$6,151
Atorvastatin Calcium235$4,507
Levothyroxine Sodium288$3,666
Gabapentin120$2,940
Omeprazole157$2,929
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$2,042

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$32$61,41154 claims
PfizerEliquis$37$41,87537 claims
Lilly USA, LLCMounjaro$54$26,58326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Bartlesville

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →